Document Detail


Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroids?
MedLine Citation:
PMID:  9694048     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Our objective was to determine whether a purified protein derivative (PPD) skin test and subsequent isoniazid administration to patients with systemic rheumatic disease, who react positively and are about to receive corticosteroids, is necessary. For this purpose, 451 unselected patients with systemic rheumatic diseases, such as rheumatoid arthritis, giant cell arteritis, polymyalgia rheumatica, systemic lupus erythematosus, scleroderma, poly- and dermatomyositis, mixed connective tissue disease, eosinophilic fasciitis, systemic necrotising vasculitis and Behçet's disease, were observed over a 6-year period. All patients had been started on steroids after commencement of the study and had received the drug for at least 1 year by the end of the study. A chest X-ray was performed before entry, every 6 months for the first year and yearly thereafter. A PPD skin test had been performed in 40 patients by other physicians, but it was our policy to omit the test. We divided our patients into age groups by decades. Steroid dosage varied according to diagnosis and severity. An initial chest X-ray revealed old inactive tuberculosis in 65 patients. During the follow-up period, none of the patients exhibited clinical or radiological evidence of reactivations of tuberculosis. However, at least 184 of the patients would have had a positive PPD skin test reaction, if tested. This figure is derived from the results of several studies on Greek army recruits whose current ages correspond to those of our patients. In conclusion, our results suggest that screening with a PPD and isoniazid prophylaxis, with all the potential risks for those who test positive, may not be necessary in patients with systemic rheumatic disease who will receive steroids.
Authors:
A P Andonopoulos; C Safridi; D Karokis; A Bounas
Related Documents :
76388 - Immunofluorescence of the skin in allergic diseases: an investigation of patients with ...
18058188 - Analysis of c-myc, pai-1 and upar in patients with incisional hernias.
19367038 - Severe hypersensitivity dermatitis and liver dysfunction induced by occupational exposu...
7746298 - Association between malassezia furfur colonization and seborrhoeic dermatitis in aids p...
22586418 - Vitreo-retinal hemorrhage after thrombolysis in a patient with acute ischemic stroke: a...
12114278 - Post-menopause is the main risk factor for developing isolated pulmonary hypertension i...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinical rheumatology     Volume:  17     ISSN:  0770-3198     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  1998  
Date Detail:
Created Date:  1998-10-20     Completed Date:  1998-10-20     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  BELGIUM    
Other Details:
Languages:  eng     Pagination:  181-5     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Patras School of Medicine, Rio Patras, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / administration & dosage*
Adult
Aged
Aged, 80 and over
Antitubercular Agents / administration & dosage*
Confidence Intervals
Drug Interactions
Female
Follow-Up Studies
Humans
Isoniazid / administration & dosage*
Male
Middle Aged
Physician's Practice Patterns
Rheumatic Diseases / complications,  diagnosis,  drug therapy*
Risk Assessment
Tuberculin Test*
Tuberculosis / complications,  diagnosis,  prevention & control*
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Antitubercular Agents; 54-85-3/Isoniazid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Metabotropic glutamate receptor activation in vivo induces intraneuronal amyloid immunoreactivity in...
Next Document:  Thrombomodulin levels in Behçet's disease with and without the factor V Leiden mutation.